Brian Wansink, Ph.D., and Pierre Chandon, Ph.D.
Conventional wisdom holds that obese people intentionally underestimate the caloric content of their meals to a greater extent than normal-weight people do. Drs. Wansink and Chandon devised two studies that show that caloric underestimation in obese people is instead attributable to their choosing larger meals. This article has important implications for the care of overweight and obese patients.
Diet therapy and nutrition
Complications and comorbidities — Obesity
Pratima Kumar, M.D., and Charles A. Reasner, M.D.
A 46-year-old woman experiencing grand mal seizures and hypoglycemia was found to have a mass in her pancreas. Drs. Kumar and Reasner describe this case of insulinoma and review the epidemiology, diagnosis, and treatment of the condition.
Complications and comorbidities — Insulinoma
The Case for Exenatide as a Treatment Option Before Insulin in Patients with Type 2 Diabetes (pages 14-20)
Robert R. Henry, M.D., Brandon Walsh, Ph.D., John H. Holcombe, M.D., and Ted Okerson, M.D.
Insulin is the recommended treatment for people with Type 2 diabetes whose HbA1C levels are suboptimal despite oral drugs and lifestyle modifications. The authors examine three long-term trials of exenatide (Byetta) and make the case for its use before insulin.
Drug treatment — Incretin mimetics
Drug treatment — Insulin
Kendall M. Campbell, M.D., and James R. Taylor, Pharm.D., C.D.E.
About 23% of people with Type 2 diabetes have chronic kidney disease, and sulfonylureas are a common treatment in these patients. In this article, Drs. Campbell and Taylor offer practical guidance for the use of sulfonylureas in patients with renal insufficiency.
Complications and comorbidities — Nephropathy
Drug treatment — Sulfonylureas
The 2008 ADA/EASD Algorithm for the Treatment of Type 2 Diabetes—Some Things Change but Most Stay the Same (pages 25-26)
Charles A. Reasner, M.D.
The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have released a new algorithm for the treatment of Type 2 diabetes. Many of the recommendations remain the same from the original 2006 algorithm, but a few have changed. The Editor takes a tour through the recommendations, pausing on those that are new and noteworthy.
Management strategies and tools — Strategies for glycemic control